Adial Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ADIL research report →
Range $6 – $11
Price Chart
About the company
Adial Pharmaceuticals, Inc. is a biopharmaceutical enterprise operating at the clinical stage, dedicated to researching and developing innovative therapeutic options for the management and prevention of addiction and associated disorders. Its primary investigational compound, AD04, functions as a selective serotonin-3 antagonist and is currently undergoing pivotal Phase III clinical trials for the treatment of alcohol use disorder.
- CEO
- Cary John Claiborne
- IPO
- 2018
- Employees
- 5
- HQ
- Glen Allen, VA, US
Get TickerSpark's AI analysis on ADIL
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $10.45M
- P/E
- -0.24
- Fwd P/E
- 9.48
- PEG
- 0.01
- P/S
- 0.00
- P/B
- 117.91
- EV/EBITDA
- 0.32
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -1693.21%
- ROIC
- -240.64%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-7,799,462
- Net Income
- $-7,977,171+39.6%
- EPS
- $-11.93+32.8%
- OCF Growth
- +6.2%
- FCF Growth
- +6.2%
- 52W High
- $10.75
- 52W Low
- $1.31
- 50D MA
- $4.81
- 200D MA
- $3.43
- Beta
- 1.50
- RSI (14)
- 40
- Avg Volume
- 57.75K
No earnings-call transcripts are available for ADIL yet.
- Free Float
- 90.8%
- Shares Outstanding
- 2.63M
- Float Shares
- 2.38M
of shares held by institutions
15 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Stonepine Capital Management, LLC | 727.56K | ▲ 727.56K |
| Vanguard Group Inc | 156.02K | 0 |
| Jane Street Group, LLC | 32.12K | ▲ 32.12K |
| Citadel Advisors LLC | 29.55K | ▲ 29.55K |
| Stonex Group Inc. | 19.70K | ▲ 19.70K |
| Ubs Group AG | 19.15K | ▲ 18.61K |
| Geode Capital Management, LLC | 12.39K | ▼ 11.86K |
| China Universal Asset Management Co., Ltd. | 8.00K | ▲ 8.00K |
| Vanguard Fiduciary Trust Co | 5.88K | 0 |
| Vanguard Capital Management LLC | 5.83K | ▲ 5.47K |
| Manchester Capital Management LLC | 1.92K | 0 |
| Tower Research Capital LLC (Trc) | 1.42K | ▲ 63 |
Held by 6 ETFs
Biggest fund positions in ADIL by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 17, 26 | Young Wendy B. | other | 25,666 |
| Jul 16, 26 | Coastlands Capital LP | buy | 1,233 |
| Jul 14, 26 | Coastlands Capital LP | buy | 2,000 |
| Jul 10, 26 | Coastlands Capital LP | buy | 1,700 |
| Jul 9, 26 | Coastlands Capital LP | buy | 10,053 |
| Jun 29, 26 | Coastlands Capital LP | buy | 25,000 |
| Jun 24, 26 | Coastlands Capital LP | other | 0 |
| Jun 24, 26 | Coastlands Capital LP | other | 3,637,818 |
| Jun 12, 26 | Davidson Matt | other | 232,417 |
| Jun 12, 26 | Davidson Matt | other | 232,417 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ADIL coverage
Recent articles, reports, and earnings notes.
No research on ADIL yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ADIL report →Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Sep 30
Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Aug 25
Adial Pharmaceuticals Reports 2026 Second Quarter Financial Results and Provides Business Update
globenewswire.com · Aug 17
Adial Pharmaceuticals Expands Executive Leadership Team and Closes PIPE Financing
globenewswire.com · Jun 16
Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing
globenewswire.com · Jun 11
Adial Pharmaceuticals Reports 2026 First Quarter Financial Results and Provides Business Update
globenewswire.com · May 11
Adial Pharmaceuticals Advances IP Portfolio with New U.S. Utility Patent Application, Positioning for Potential Market Exclusivity Through 2045
globenewswire.com · Apr 29
Adial Pharmaceuticals Submits Application to FDA Commissioner’s National Priority Voucher (CNPV) Pilot Program for AD04 Clinical Development Program
globenewswire.com · Apr 27
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.